Literature DB >> 25045333

Medical therapy for pediatric vascular anomalies.

Judith F Margolin1, Heather Mills Soni1, Sheena Pimpalwar2.   

Abstract

Vascular anomalies (VAs) comprise a large variety of individual diagnoses that in different phases of treatment require a diverse number of medical specialists to provide optimal care. Medical therapies include agents usually associated with cancer chemotherapy, such as vincristine, as well more immunomodulatory types of drugs, such as glucocorticoids and sirolimus. These immunomodulating drugs are being successfully applied in cases that are typically categorized as vascular tumors, including kaposiform hemangioendothelioma (KHE) and tufted angioma (TA), as well as some of the more invasive types of vascular malformations (i.e., microcystic lymphatic malformations and blue rubber bleb nevus syndrome (BRBNS). These therapies need to be combined with good supportive care, which often involves anticoagulation, antimicrobial prophylaxis, and comprehensive pain and symptom-relief strategies, as well as appropriate drug monitoring and management of side effects of medical treatment. The optimal care of these patients frequently involves close collaboration between surgeons, interventional and conventional radiologists, medical subspecialists, and nurses.

Entities:  

Keywords:  blue rubber bleb nevus syndrome; chemotherapy; kaposiform hemangioendothelioma; sirolimus; tufted angioma; vascular anomalies

Year:  2014        PMID: 25045333      PMCID: PMC4078199          DOI: 10.1055/s-0034-1376264

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.314


  31 in total

1.  Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.

Authors:  Brook E Tlougan; Margaret T Lee; Beth A Drolet; Ilona J Frieden; Denise M Adams; Maria C Garzon
Journal:  J Pediatr Hematol Oncol       Date:  2013-11       Impact factor: 1.289

Review 2.  Current classification and terminology of pediatric vascular anomalies.

Authors:  Ramya Kollipara; Laura Dinneen; Kenny E Rentas; Megan R Saettele; Suchit A Patel; Douglas C Rivard; Lisa H Lowe
Journal:  AJR Am J Roentgenol       Date:  2013-11       Impact factor: 3.959

Review 3.  The role of the hematologist/oncologist in the care of patients with vascular anomalies.

Authors:  Denise M Adams; Mary Sue Wentzel
Journal:  Pediatr Clin North Am       Date:  2008-04       Impact factor: 3.278

Review 4.  mTOR-targeted therapy of cancer with rapamycin derivatives.

Authors:  S Vignot; S Faivre; D Aguirre; E Raymond
Journal:  Ann Oncol       Date:  2005-02-22       Impact factor: 32.976

5.  Evaluation of terminology for vascular anomalies in current literature.

Authors:  Aladdin H Hassanein; John B Mulliken; Steven J Fishman; Arin K Greene
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

6.  Sirolimus for the treatment of complicated vascular anomalies in children.

Authors:  Adrienne M Hammill; MarySue Wentzel; Anita Gupta; Stephen Nelson; Anne Lucky; Ravi Elluru; Roshni Dasgupta; Richard G Azizkhan; Denise M Adams
Journal:  Pediatr Blood Cancer       Date:  2011-03-28       Impact factor: 3.167

Review 7.  Pediatric thrombophilia.

Authors:  Janet Y K Yang; Anthony K C Chan
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 8.  Kaposiform hemangioendothelioma.

Authors:  Y Fernández; M Bernabeu-Wittel; J S García-Morillo
Journal:  Eur J Intern Med       Date:  2008-08-15       Impact factor: 4.487

Review 9.  Medical management of vascular anomalies.

Authors:  Francine Blei
Journal:  Facial Plast Surg       Date:  2012-11-27       Impact factor: 1.446

10.  Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!

Authors:  Claudia S Vetter-Kauczok; Philipp Ströbel; Eva B Bröcker; Jürgen C Becker
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  11 in total

Review 1.  Advances in the Medical Management of Vascular Anomalies.

Authors:  Kiersten W Ricci
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

2.  Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.

Authors:  Kiersten W Ricci; Adrienne M Hammill; Paula Mobberley-Schuman; Stephen C Nelson; Julie Blatt; Julia L Glade Bender; Catherine C McCuaig; Anna Synakiewicz; Ilona J Frieden; Denise M Adams
Journal:  Pediatr Blood Cancer       Date:  2019-01-22       Impact factor: 3.167

3.  Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.

Authors:  Denise M Adams; Cameron C Trenor; Adrienne M Hammill; Alexander A Vinks; Manish N Patel; Gulraiz Chaudry; Mary Sue Wentzel; Paula S Mobberley-Schuman; Lisa M Campbell; Christine Brookbank; Anita Gupta; Carol Chute; Jennifer Eile; Jesse McKenna; Arnold C Merrow; Lin Fei; Lindsey Hornung; Michael Seid; A Roshni Dasgupta; Belinda H Dickie; Ravindhra G Elluru; Anne W Lucky; Brian Weiss; Richard G Azizkhan
Journal:  Pediatrics       Date:  2016-01-18       Impact factor: 7.124

4.  Therapeutic effect of laser on pediatric oral soft tissue problems: a systematic literature review.

Authors:  Farshad Khosraviani; Sara Ehsani; Mona Fathi; Amir Saberi-Demneh
Journal:  Lasers Med Sci       Date:  2019-07-15       Impact factor: 3.161

5.  Sirolimus for the treatment of children with various complicated vascular anomalies.

Authors:  Herwig Lackner; Anna Karastaneva; Wolfgang Schwinger; Martin Benesch; Petra Sovinz; Markus Seidel; Daniela Sperl; Sofia Lanz; Emir Haxhija; Friedrich Reiterer; Erich Sorantin; Christian E Urban
Journal:  Eur J Pediatr       Date:  2015-06-04       Impact factor: 3.183

6.  Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.

Authors:  Alaa M Alaqeel; Nuha A Alfurayh; Alanoud A Alhedyani; Saad M Alajlan
Journal:  JAAD Case Rep       Date:  2016-12-05

7.  Sirolimus alternative to blood transfusion as a life saver in blue rubber bleb nevus syndrome: A case report.

Authors:  Ke-Ling Wang; Shu-Fang Ma; Ling-Yu Pang; Meng-Na Zhang; Lin-Yan Hu; Meng-Jia Liu; Li-Ping Zou
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

8.  Successful Management of Blue Rubber Bleb Nevus Syndrome (BRBNS) with Sirolimus.

Authors:  Ugochi O Ogu; Ghada Abusin; Rolla F Abu-Arja; Janice M Staber
Journal:  Case Rep Pediatr       Date:  2018-10-08

Review 9.  Clinical Outcomes for Systemic Corticosteroids Versus Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma.

Authors:  Xiaohan Liu; Jiaying Li; Xinhua Qu; Weili Yan; Ling Zhang; Shanyong Zhang; Chi Yang; Jiawei Zheng
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy.

Authors:  Ilaria Amodeo; Mariarosa Colnaghi; Genny Raffaeli; Giacomo Cavallaro; Fabrizio Ciralli; Silvana Gangi; Ernesto Leva; Lorenzo Pignataro; Irene Borzani; Lorenza Pugni; Fabio Mosca
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.